Freenome, Inc. (FRNM)
Healthcare · NGM
Price as at 30 Sept 2026, 13:35 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Freenome, Inc. trades at $16.02. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
Our moat model scores it 9 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
About Freenome, Inc.
Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
FRNM passes 2 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
FRNM peers
The largest companies in the same industry (Diagnostics & Research), then in the same sector.
- TMO Thermo Fisher Scientific Inc.
- WAT Waters Corporation
- DGX Quest Diagnostics Incorporated
- ICLR ICON Public Limited Company
- CRL Charles River Laboratories International, Inc.
- QIA.DE Qiagen N.V.
- BLLN BillionToOne, Inc.
- SHC Sotera Health Company
Every healthcare company we cover is on the Healthcare hub.
Common questions
Where does SteadyShares get its FRNM data?
Fundamentals for FRNM come from company filings and exchange data, as listed on NGM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 13:35 UTC and is delayed. Our data quality score for this company is 63/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for FRNM, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.